BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...plc (LSE:AZN; NASDAQ:AZN). His brother, Wenchao, is a University of Pennsylvania professor of systems pharmacology and translational therapeutics...
BioCentury | Feb 1, 2020
Preclinical News

Cardior eyes heart failure cure with miRNA inhibitor

Cardior unveiled data on Friday that demonstrates its first clinical candidate goes beyond treating the cardiovascular symptoms of heart failure to reversing established disease in animal models. Cardior Pharmaceuticals GmbH, which spun out of Hannover...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

...013100, a small molecule eIF4E inhibitor, in preclinical testing for cancer. Karo Pharma AB and Translational Therapeutics Inc....
BioCentury | Aug 15, 2016
Emerging Company Profile

Restraining translation

...solid tumors. The company is also developing a preclinical orally administered analog, ON 013100 . Translational Therapeutics...
...New York, N.Y. Effector Therapeutics Inc., San Diego, Calif. Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa. Translational Therapeutics Inc....
BioCentury | Jan 28, 2016
Strategy

CIRM's endgame

In the latest effort to make good on promises made to the voters who created the California Institute for Regenerative Medicine (CIRM) in 2004, the agency has approved a strategic plan spelling out concrete goals...
BioCentury | Aug 24, 2015
Company News

New Zealand Pharmaceuticals, Fortress Biotech deal

...under a Cooperative Research and Development Agreement with NIH as part of NIH’s Center for Translational Therapeutics’...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

...testing to treat non-small cell lung cancer (NSCLC) and prostate cancer. Clavis Pharma ASA and Translational Therapeutics Inc....
BioCentury | Jan 24, 2013
Distillery Therapeutics

Indication: Neurology

...testing to treat prostate cancer and non-small cell lung cancer (NSCLC). Clavis Pharma ASA and Translational Therapeutics Inc....
BioCentury | Dec 13, 2012
Cover Story

Translating autism

...is in Phase II testing to treat non-small cell lung cancer (NSCLC) and prostate cancer. Translational Therapeutics Inc....
...Boston, Mass. McGill University , Montreal, Quebec, Canada New York University , New York, N.Y. Translational Therapeutics Inc....
BioCentury | Dec 6, 2012
Distillery Therapeutics

Indication: Neurology

...testing to treat prostate cancer and non-small cell lung cancer (NSCLC). Clavis Pharma ASA and Translational Therapeutics Inc....
Items per page:
1 - 10 of 15
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...plc (LSE:AZN; NASDAQ:AZN). His brother, Wenchao, is a University of Pennsylvania professor of systems pharmacology and translational therapeutics...
BioCentury | Feb 1, 2020
Preclinical News

Cardior eyes heart failure cure with miRNA inhibitor

Cardior unveiled data on Friday that demonstrates its first clinical candidate goes beyond treating the cardiovascular symptoms of heart failure to reversing established disease in animal models. Cardior Pharmaceuticals GmbH, which spun out of Hannover...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

...013100, a small molecule eIF4E inhibitor, in preclinical testing for cancer. Karo Pharma AB and Translational Therapeutics Inc....
BioCentury | Aug 15, 2016
Emerging Company Profile

Restraining translation

...solid tumors. The company is also developing a preclinical orally administered analog, ON 013100 . Translational Therapeutics...
...New York, N.Y. Effector Therapeutics Inc., San Diego, Calif. Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa. Translational Therapeutics Inc....
BioCentury | Jan 28, 2016
Strategy

CIRM's endgame

In the latest effort to make good on promises made to the voters who created the California Institute for Regenerative Medicine (CIRM) in 2004, the agency has approved a strategic plan spelling out concrete goals...
BioCentury | Aug 24, 2015
Company News

New Zealand Pharmaceuticals, Fortress Biotech deal

...under a Cooperative Research and Development Agreement with NIH as part of NIH’s Center for Translational Therapeutics’...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

...testing to treat non-small cell lung cancer (NSCLC) and prostate cancer. Clavis Pharma ASA and Translational Therapeutics Inc....
BioCentury | Jan 24, 2013
Distillery Therapeutics

Indication: Neurology

...testing to treat prostate cancer and non-small cell lung cancer (NSCLC). Clavis Pharma ASA and Translational Therapeutics Inc....
BioCentury | Dec 13, 2012
Cover Story

Translating autism

...is in Phase II testing to treat non-small cell lung cancer (NSCLC) and prostate cancer. Translational Therapeutics Inc....
...Boston, Mass. McGill University , Montreal, Quebec, Canada New York University , New York, N.Y. Translational Therapeutics Inc....
BioCentury | Dec 6, 2012
Distillery Therapeutics

Indication: Neurology

...testing to treat prostate cancer and non-small cell lung cancer (NSCLC). Clavis Pharma ASA and Translational Therapeutics Inc....
Items per page:
1 - 10 of 15